WO2003051379A1 - Outer membrane vesicles from gram negative bacteria and use as a vaccine - Google Patents
Outer membrane vesicles from gram negative bacteria and use as a vaccine Download PDFInfo
- Publication number
- WO2003051379A1 WO2003051379A1 PCT/GB2002/005718 GB0205718W WO03051379A1 WO 2003051379 A1 WO2003051379 A1 WO 2003051379A1 GB 0205718 W GB0205718 W GB 0205718W WO 03051379 A1 WO03051379 A1 WO 03051379A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- omvs
- vesicles
- species
- composition
- gram negative
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 59
- 239000012528 membrane Substances 0.000 title claims abstract description 18
- 241000894006 Bacteria Species 0.000 title claims description 46
- 239000000203 mixture Substances 0.000 claims abstract description 151
- 239000000427 antigen Substances 0.000 claims abstract description 58
- 102000036639 antigens Human genes 0.000 claims abstract description 58
- 108091007433 antigens Proteins 0.000 claims abstract description 58
- 238000000034 method Methods 0.000 claims description 66
- 241000894007 species Species 0.000 claims description 65
- 230000000890 antigenic effect Effects 0.000 claims description 44
- 239000002502 liposome Substances 0.000 claims description 37
- 241000588650 Neisseria meningitidis Species 0.000 claims description 36
- 150000002632 lipids Chemical class 0.000 claims description 28
- 230000001717 pathogenic effect Effects 0.000 claims description 27
- 241000588653 Neisseria Species 0.000 claims description 25
- 239000002158 endotoxin Substances 0.000 claims description 23
- 241001212279 Neisseriales Species 0.000 claims description 22
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 22
- 241001465754 Metazoa Species 0.000 claims description 20
- 241000588649 Neisseria lactamica Species 0.000 claims description 20
- 241000282412 Homo Species 0.000 claims description 16
- 238000000605 extraction Methods 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 16
- 244000052769 pathogen Species 0.000 claims description 15
- 101710116435 Outer membrane protein Proteins 0.000 claims description 13
- 229940009976 deoxycholate Drugs 0.000 claims description 10
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 10
- 208000027096 gram-negative bacterial infections Diseases 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 229920001184 polypeptide Polymers 0.000 claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 241000588654 Neisseria cinerea Species 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 claims description 6
- 241000588673 Neisseria elongata Species 0.000 claims description 5
- 241000588651 Neisseria flavescens Species 0.000 claims description 5
- 241001464937 Neisseria perflava Species 0.000 claims description 5
- 241000588660 Neisseria polysaccharea Species 0.000 claims description 5
- 241000588645 Neisseria sicca Species 0.000 claims description 5
- 241001136170 Neisseria subflava Species 0.000 claims description 5
- 239000007983 Tris buffer Substances 0.000 claims description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 5
- 241000589291 Acinetobacter Species 0.000 claims description 4
- 241000588807 Bordetella Species 0.000 claims description 4
- 241000589562 Brucella Species 0.000 claims description 4
- 241000606790 Haemophilus Species 0.000 claims description 4
- 241001454354 Kingella Species 0.000 claims description 4
- 241000589248 Legionella Species 0.000 claims description 4
- 208000007764 Legionnaires' Disease Diseases 0.000 claims description 4
- 241000588621 Moraxella Species 0.000 claims description 4
- 241000588652 Neisseria gonorrhoeae Species 0.000 claims description 4
- 241000589516 Pseudomonas Species 0.000 claims description 4
- 241000607734 Yersinia <bacteria> Species 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 206010027249 Meningitis meningococcal Diseases 0.000 claims description 3
- 201000010924 Meningococcal meningitis Diseases 0.000 claims description 3
- 206010027280 Meningococcal sepsis Diseases 0.000 claims description 3
- 241000606750 Actinobacillus Species 0.000 claims description 2
- 241000588832 Bordetella pertussis Species 0.000 claims description 2
- 241000589876 Campylobacter Species 0.000 claims description 2
- 241000606161 Chlamydia Species 0.000 claims description 2
- 108010053187 Diphtheria Toxin Proteins 0.000 claims description 2
- 102000016607 Diphtheria Toxin Human genes 0.000 claims description 2
- 241000589989 Helicobacter Species 0.000 claims description 2
- 201000005505 Measles Diseases 0.000 claims description 2
- 108010052285 Membrane Proteins Proteins 0.000 claims description 2
- 102000018697 Membrane Proteins Human genes 0.000 claims description 2
- 241000605894 Porphyromonas Species 0.000 claims description 2
- 241000607142 Salmonella Species 0.000 claims description 2
- 241000607720 Serratia Species 0.000 claims description 2
- 108010055044 Tetanus Toxin Proteins 0.000 claims description 2
- 108010031133 Transferrin-Binding Protein A Proteins 0.000 claims description 2
- 108010031127 Transferrin-Binding Protein B Proteins 0.000 claims description 2
- 241000700647 Variola virus Species 0.000 claims description 2
- 210000000170 cell membrane Anatomy 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 101150087392 pilQ gene Proteins 0.000 claims description 2
- 229940118376 tetanus toxin Drugs 0.000 claims description 2
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 claims description 2
- 230000006806 disease prevention Effects 0.000 claims 2
- 241000193738 Bacillus anthracis Species 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 239000006194 liquid suspension Substances 0.000 claims 1
- 239000000872 buffer Substances 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 14
- 230000001580 bacterial effect Effects 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 10
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 239000008188 pellet Substances 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 5
- 230000000717 retained effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 239000000232 Lipid Bilayer Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000005526 G1 to G0 transition Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000000635 electron micrograph Methods 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 208000037941 meningococcal disease Diseases 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 3
- 229960004906 thiomersal Drugs 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- AZXKALLRCOCGBV-UHFFFAOYSA-N 1-phenyl-2-(propan-2-ylamino)hexan-1-one Chemical compound CCCCC(NC(C)C)C(=O)C1=CC=CC=C1 AZXKALLRCOCGBV-UHFFFAOYSA-N 0.000 description 2
- 241000588722 Escherichia Species 0.000 description 2
- 241000606768 Haemophilus influenzae Species 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241000607479 Yersinia pestis Species 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 208000002352 blister Diseases 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000002525 ultrasonication Methods 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000034762 Meningococcal Infections Diseases 0.000 description 1
- 241000588655 Moraxella catarrhalis Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108700018753 Neisseria porin Proteins 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 108010090127 Periplasmic Proteins Proteins 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 244000037640 animal pathogen Species 0.000 description 1
- 229960002235 anthrax antigen Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001948 anti-meningococcal effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000003508 chemical denaturation Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- TXWRERCHRDBNLG-UHFFFAOYSA-N cubane Chemical compound C12C3C4C1C1C4C3C12 TXWRERCHRDBNLG-UHFFFAOYSA-N 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 244000000058 gram-negative pathogen Species 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- 230000004726 long-term protective immunity Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000005789 organism growth Effects 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/739—Lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/825—Bacteria
Definitions
- the present invention is in the field of compositions comprising vesicles, such as liposomes and outer membrane vesicles (OMVs) obtainable from Gram negative bacteria, methods of making such compositions and vaccines based thereon.
- OMVs outer membrane vesicles
- the invention relates to vaccines and pharmaceutical compositions comprising OMVs obtained from Neisse a species.
- Neisseha meningitidis (the meningococcus) is the organism that causes meningococcal meningitis and is of particular importance as a worldwide health problem. In many countries the incidence of this disease is increasing. N.
- meningitidis is also responsible for meningococcal septicaemia, which is associated with rapid onset and high mortality, with around 22% of cases proving fatal.
- Other Gram negative bacteria are responsible for a range of human infections including meningitis (H. influenzae), plague (Y. pestis), gastroenteritis (£. coli), venereal disease (N. gonorrhoeae) and nosocomial infection (P. aeruginosa).
- OMVs outer membrane vesicles
- blebs outer membrane vesicles
- OMVs outer membrane proteins
- LPS lipopolysaccharide
- OMVs isolated from N. meningitidis are combined with heterologous antigens, e.g. Tbp, or a genetically modified N. meningitidis expresses such antigens recombinantly and antigen enriched OMVs are derived therefrom.
- heterologous antigens e.g. Tbp
- WO-A-01/09350 describes vaccine compositions comprising OMVs from N. meningitidis, M. catarrhalis and H. influenzae, where in certain embodiments these organisms have been genetically modified to overexpress particular immunogenic moieties.
- a further OMV based vaccine composition is known as the HexamenTM or Dutch vaccine (Cartwright et al Naccine 17 (1999), pp2612-2619).
- the HexamenTM vaccine composition comprises N. meningitidis OMVs that include six different PorA proteins that are recombinantly produced using two vaccine strains of N. meningitidis, PL16215 and PL10124. Each strain is capsule negative and produces three different PorA proteins, CPS- P1.7,16;P1.5,2; P1.19,15 and CPS P1.5 C ,10; P1.12,13; P1.7 h ,4 respectively.
- PorA is an immunodominant antigen, meaning that it masks most other antigens presented on the OMV surface - i.e. HexamenTM vaccine is heavily biased towards PorA as the protective antigen. This, in turn, leads to selection pressure in the population towards strains of N. meningitidis that express PorAs that are antigenically different to those in the HexamenTM vaccine. There is, therefore, a risk that strains of N. meningitidis that are not protected against by the HexamenTM vaccine will predominate in time, resulting in ongoing efforts to continually modify the vaccine to protect against strains currently infecting and causing disease in the human population.
- OMV vaccine composition that provides broad spectrum protection to infection from a number of bacterial species and at least a wide range of strains within a single bacterial genus. It would be particularly desirable to produce an OMV-based vaccine that provides broad spectrum, long term protection against disease caused by a range of strains of Gram negative bacteria, and especially N. meningitidis.
- the present invention provides methods and compositions comprising vesicles, especially OMVs, and vaccine compositions based thereon which can provide a broad scope of protection to infection from Gram negative bacterial pathogens, such as N. meningitidis.
- compositions and vaccines of the present invention are derived from a diversity of Gram negative bacterial sources, thus allowing the composition to present a broad spectrum of antigens to the host immune system, and thereby generating broad spectrum protective immunity.
- the present invention also provides methods of combining vesicles, especially OMVs, vesicles obtained thereby and vaccine compositions based thereon. Advantages of the combining include control of vesicle content and/or facilitation of antigen combinations in the resultant vesicles.
- Gram negative bacteria are those bacteria that fail to resist decolourisation in the commonly known Gram staining method. Gram negative bacteria are characterised by a complex multilayer cell wall and often possess an outer layer polysaccharide capsule - e.g. N. meningitidis, although in some species this capsule is absent - e.g. N. lactamica.
- pathogenic refers to an organism that is capable of causing disease, particularly in animals and especially in humans.
- non-pathogenic refers to organisms that do not cause disease in animals, in particular in humans.
- the term includes commensal organisms.
- Commensal organisms are those that can colonize a host organism without signs of disease.
- Examples of commensal organisms include the commensal Neisseha species, such as N. lactamica, N. sicca, N. cinerea, N. perflava, N. subflava, N. elongata, N. flavescens, and N. polysaccharea.
- Outer membrane vesicles are vesicles formed or derived from fragments of the outer membrane of a Gram negative bacterium.
- OMVs typically comprise outer membrane proteins (OMPs), lipids, phospholipids, periplasmic material and lipopolysaccharide (LPS).
- OMVs especially pathogens like N. meningitidis, often shed OMVs during virulent infections in a process known as blebbing.
- OMVs can also be obtained from Gram negative bacteria via a number of chemical denaturation processes described in more detail in the Examples below.
- Liposomes comprising a lipid bilayer and typically enclosing an aqueous core, can be regarded for the purposes of the present invention as constituting a synthetic equivalent to OMVs, and embodiments of the invention described with reference to OMVs apply mutatis mutandis to embodiments carried out with and relating to liposomes.
- a distinction between liposomes and OMVs may be made for example in embodiments in which control of content of a liposome is possible whereas OMV content is not so readily controllable.
- a "vaccine” as referred to herein is defined as a pharmaceutical or therapeutic composition used to inoculate an animal in order to immunize the animal against infection by an organism, typically a pathogenic organism.
- a vaccine will typically comprise one or more antigens derived from one or more organisms which on administration to an animal will stimulate active immunity and protect that animal against infection with these or related pathogenic organisms.
- Vaccine compositions that are formulated as pharmaceuticals will typically comprise a carrier. If in solution or in liquid aerosol suspension, suitable carriers can include saline solution, sucrose solution, or other pharmaceutically acceptable buffer solutions. An aerosol formulation will typically additionally comprise a surfactant.
- Alternative vaccine compositions include microencapsulated OMV compositions. Such microcapsules with generally comprise a biocompatible polymer shell or core, such as made from polylactide-co-glycolide (PLG).
- Vaccine compositions can additionally comprise an adjuvant, for example where administration is via the parenteral route. Suitable adjuvants include aluminium hydroxide.
- Vaccines are suitably administered to an animal via a number routes.
- Certain proteins can be recombinantly expressed in Gram negative bacteria and thereby enable enrichment or alteration of the antigenic profile of the bacterial outer membrane. Genetic modification of a bacterial source organism thereby allows for manipulation of the antigenic profile of OMVs that are obtained from these organisms. When proteins that are not normally present in the bacterial outer membrane, and thus in an OMV derived therefrom, are introduced via recombinant expression techniques, these "non-native" proteins and polypeptides are described as heterologous antigens.
- the contents of WO-A-00/25811 and WO-A-01/09350 are incorporated herein.
- the vaccine comprises OMVs rather than live attenuated or dead pathogenic organisms which can pose a greater risk of infection or toxicity.
- a first aspect of the invention mixes different vesicle preparations. This may be done to alter the immunogenicity of a first OMV preparation or to mix useful properties in respective preparations.
- the invention thereby provides compositions comprising vesicles derived from two or more sources.
- the vesicles are preferably lipid vesicles comprising a lipid bilayer surrounding an aqueous core.
- the lipid vesicles are of unilamellar structure (i.e. a single lipid bilayer surrounds the aqueous core), although multilammellar lipid vesicles are also suitably used in the compositions of the invention.
- lipid vesicles are preferably synthetic vesicles such as liposomes or obtained from bacteria such as outer membrane vesicles (OMVs) by extraction of naturally occurring OMVs (N-OMVs) or using a detergent extraction (D-OMVs). They typically have sizes in the nanomolar to micromolar range, e.g. from 1 nm to 100 ⁇ M, more typically from 10nm to10 ⁇ m and preferably from 30nm to 1 ⁇ m.
- Antigenic components can be located in any or all of the three main compartments of the lipid vesicle, namely:
- lipid vesicle 1. attached to the either the interior or exterior surface of the lipid vesicle, for example via a membrane anchor domain, or attachment to a lipid moiety;
- the antigenic component is itself a hydrophobic or lipid based entity
- liposomes are utilised in the compositions and methods of the invention these can typically contain a number of different lipids and fatty acids.
- Suitable lipids for inclusion in liposomes of the invention include but are not limited to phosphatidylinositol-(4,5)-diphosphate, phosphatidylserine, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, cholesterol, beta-oleolyl-gamma- palmitoyl, certain lipopolysaccharides and galactocebrosides.
- Liposomes can be obtained commercially from a number of sources and methods for preparing liposomes suitable for use in the invention are known in the art.
- the lipid vesicles for use in the invention can be enriched and/or supplemented with preferred antigenic components.
- Regimes for supplementing the lipid vesicles ' include via direct combination in vitro where an energetic combination step can optionally be applied to facilitate integration of the antigenic component into one or more of the three aforementioned lipid vesicle compartments.
- energetic combination methods include homogenisation, ultrasonication, extrusion and combinations thereof.
- liposomes are more easily controlled by modifying the lipid composition of the bilayer.
- OMVs are the preferred lipid vesicle. Further advantages of using OMVs are that antigenic components can be synthesised in the host organism from which the OMV is obtained thereby providing a convenient method for integrating a preferred antigenic component into a lipid vesicle.
- lipid vesicle of the invention In situations where a particular component is not desired in a lipid vesicle of the invention, for example endotoxin, different options apply when using liposomes or OMVs. It is apparent that as the composition of the liposome is synthetically controlled the non-desired component is simply not added to the liposome. This represents a further advantage associated with the use of liposomes.
- OMVs are preferred as the lipid vesicle, the OMVs can be obtained from organisms that are naturally free or low in the non-desired component, for example commensal organisms. Alternatively, knock out organisms can be generated where genes coding for or regulating the production of the non-desired component are deleted or silenced.
- the lipid vesicles for use in the invention can also comprise a biologically active component, other than an antigen, within the aqueous centre/core.
- This component is suitably selected from soluble adjuvants, cytokines, immunomodulatory agents, pharmaceuticals, excipients, proteins, polypeptides and pharmacologically or pharmaceutically active agents.
- the invention also provides a composition comprising OMVs obtained from at least two different species of Gram negative bacteria, wherein at least one of said species is a non-pathogenic species.
- Gram negative species especially suitable for use in the invention include those selected from Neisseha, Moraxella, Kingella, Acinetobacter, Brucella, Bordetella, Porphyromonas, Actinobacillus, Borelia, Serratia, Campylobacter, Helicobacter, Haemophilus, Escherichia, Legionella, Salmonella, Pseudomonas and Yersinia.
- the composition comprises a pathogenic species is selected from strains of N. meningitidis.
- the non-pathogenic species can suitably be any non-pathogenic Gram negative species.
- the composition comprises OMVs obtained from a commensal Neisseha.
- compositions of the invention need not be limited to comprising OMVs from only two sources.
- the invention also provides compositions comprising OMVs from a plurality of Gram negative bacterial sources, from as few as three sources up to many tens or more. It is feasible for a library of a multiplicity of OMVs to be constructed and hence certain combinations of OMVs can be formulated into compositions, according to precise requirements, so as to provide a particular predetermined spectrum of vaccination coverage. For example, where a certain strain of pathogen is prevalent in a particular geographical area, OMVs specific to this pathogen are incorporated into a broad spectrum vaccine composition in order to provide improved local efficacy.
- Combining a plurality of OMVs in a single vaccine composition provides a composition capable of conferring broad spectrum immunity and also enables the "dilution" of immunodominant antigens, such as PorA, which would otherwise mask the other antigens present in the composition.
- composition of the invention comprises OMVs, which OMVs are obtained from a first and at least a second different species of Neisseha, wherein: 1. the first species is a pathogenic species of Neisseha; and 2. the at least a second species is a commensal species of Neisseha.
- the composition comprises OMVs obtained from a first and at least a second different species of Neisseha, wherein:
- the first species is selected from the group comprising N. meningitidis and N. gonorrhoeae;
- the at least a second species is selected from the group comprising N. lactamica, N. sicca, N. cinerea, N. perflava, N. subflava, N. elongata, N. flavescens, and N. polysaccharea.
- some or all of the OMVs in the composition also comprise a heterologous antigen.
- Suitable heterologous antigens include cell membrane associated proteins, or periplasmic proteins, such as PorA; Cu-Zn-SOD; TspA, LbpA, LbpB, pilQ, TbpA; TbpB and/or NspA. These can also be non-neisserial, such as B. pertussis toxin, diphtheria toxin, tetanus toxin, measles antigen, HIV antigens, smallpox antigen, and/or anthrax antigen. It should be noted that the OMVs of the invention provide advantageous presentation of antigens to the host immune system, thereby enabling broad spectrum, long term protective immunity.
- a third composition of the invention is one comprising OMVs, which OMVs are obtained from a first neisserial source and at least a second neisserial source different from the first.
- source is used to refer to the genus and/or strain of Neisseha from which the OMVs are obtained or isolated. Hence, if OMVs are extracted from N. meningitidis strain K454, this is the neisserial source of the OMVs.
- the first neisserial source is a commensal Neisseha and said at least second neisserial source is a pathogenic Neisseha.
- the first neisserial source can be a commensal Neisseha and said at least second neisserial source is also a commensal Neisseha but of a different species or strain to the first.
- the first source is suitably N. lactamica and the second N. cinerea.
- the first source is N. lactamica strain Y921009 and the second source is N. lactamica strain 2086.
- a further option is to utilise different genetic mutants of the same strain.
- the invention also utilizes OMV compositions derived from neisserial sources which are genetically modified so as to recombinantly express one or more heterologous antigens.
- This can be achieved by transforming the cells with an expression vector that comprises DNA encoding the desired antigenic polypeptide.
- an endogenous polypeptide can be upregulated or modified in some way as to be expressed either on the surface or within the periplasm of the cell, and thereby incorporated into OMVs extracted from that cell.
- proteins are endogenous to the cell, their presence at abnormal levels in OMVs, can still be considered to fall within the scope of the term "heterologous antigen".
- a first neisserial source is a commensal Neisseha that expresses a first heterologous antigen and the second neisserial source is a Neisseha that expresses a second heterologous antigen different from the first antigen.
- a first neisserial source is a commensal Neisseha that expresses a first heterologous antigen and the least a second neisserial source is a commensal Neisseha of the same or a similar strain that expresses a second heterologous antigen different from the first antigen.
- Each source can further optionally express multiple heterologous antigens.
- a fourth composition of the invention comprises an OMV containing outer membrane protein (OMP) and/or lipopolysaccharide (LPS) derived from at least two different species of Gram negative bacteria, such as Neisseha.
- OMV outer membrane protein
- LPS lipopolysaccharide
- the OMV is suitably derived from two species of Neisseha which include a commensal Neisseha and a pathogenic Neisseha, from at least two species of commensal Neisseha, or even from two different strains of the same commensal species.
- the OMV can optionally further comprise one or more recombinantly expressed polypeptides.
- OMVs derived from commensals typically have LPS of lower toxicity than the LPS found in the outer membrane of pathogenic species.
- vaccine compositions comprising commensal OMVs typically elicit lesser adverse reactions than compositions comprising pathogenic OMVs.
- the LPS content of the OMV also provides an adjuvant effect which itself enhances an immune response especially in compositions that are administered intra-nasally. It is a further option to derive OMVs from LPS null mutant or LPS modified species of Gram negative bacteria, suitably in cases where potential LPS toxicity is likely to cause extreme allergic reactions.
- OMVs of the invention can be suitably mixed from sources such as Gram negative bacteria of different species or strains.
- OMVs can optionally be obtained from sources that are from the same commensal strain but where each source expresses different heterologous antigens.
- a further example of different OMVs from same strain sources is where OMVs are obtained from a Gram negative bacterial source at different phases in the organism's growth cycle. The OMVs are then combined into a single composition that represents the surface antigenicity profile of the organism throughout its growth cycle.
- a second aspect of the invention combines different vesicle preparations so as to transfer a component of one vesicle, or one type of vesicle, to another.
- liposomes are combined with liposomes, liposomes with OMVs and OMVs with OMVs.
- the invention thus provides a method of preparing a composition, comprising:-
- a further method of the second aspect, for preparing lipid vesicles comprises:- a. synthesising liposomes comprising a first antigenic component; b. obtaining OMVs from an organism, said OMVs comprising a second antigenic component; and c. mixing the liposomes of (a) with the OMVs of (b) so as to form a vesicle comprising both the first and the second antigenic component.
- a still further method of the second aspect, for preparing an OMV containing composition comprises:- 1. isolating OMVs from a first species of Gram negative bacteria, wherein said first species is either pathogenic or non-pathogenic to humans;
- the second aspect of the invention extends also to compositions obtainable and obtained using the above methods, to pharmaceutical compositions, to methods of medical treatment as herein described, to uses as herein described, all based thereon.
- the combining of the two separate compositions, containing distinct vesicles is carried out so as to effect a transfer of an antigen between the respective compositions, resulting in production of a third type of vesicle which contains antigenic components derived from both the first and the second original vesicles.
- This means of providing a vesicle with both antigenic components can be easier than, for example, carrying out a transfection of a bacteria so that it expresses both antigenic components.
- homogenous preparation of many different combinations of antigens can be prepared from starting materials comprising individual vesicles containing individual antigenic components of interest. Different antigens may be expressed at different levels in the same bacterial host. Using the above methods of combination of vesicles, by control of the starting amount / concentration of each respective vesicle, with its respective antigen, the relative amounts / concentrations of antigens in the final resultant combined vesicle can be controlled.
- a purified preparation of the third vesicles is carried out using a double-immune method.
- a first purification is carried out with an antibody (e.g. immobilized), specific for the first antigen; a second purification is then carried out using an antibody specific for the second antigen - this purifies the composition in respect of vesicles containing both antigens.
- OMVs and liposomes are suitable for the methods of the second aspect, with OMVs preferably being derived from Gram negative bacteria as previously described - though especially from Neisseria.
- a liposome containing a component other than (or in addition to) an antigen can be combined with an antigen-containing vesicle.
- one such method of preparing a composition comprises:- 1. obtaining a first composition which contains first vesicles, said vesicles having an antigenic component; 2. obtaining a second composition which contains second vesicles, said second vesicles comprising a soluble, biologically active component within aqueous cores of the vesicles; and 3. combining the first and second compositions so as to obtain a third vesicles-containing composition, wherein the third vesicles-containing composition comprises third vesicles which both comprise the antigenic component and also contain, within an aqueous core, the soluble, biologically active component.
- vesicles confer the advantage of combining, at the control of the user, the antigen from one source and the liposome contents of another, resulting in provision of further methods for preparation of vesicles for vaccination and other uses.
- liposomes comprising one or more antigenic components are combined with OMVs in a single composition. Following a fusion event in which a modified energetic combination step is employed, resulting hybrid or chimaeric lipid vesicles are formed.
- liposomes comprising one or more antigenic components are combined with OMVs in a single composition so that antigens from OMVs are exchanged or transferred to liposomes and vice versa.
- the liposomes and OMVs can be separated (for example, by centrifugation) and form distinct compositions in their own right for application as vaccine compositions as described further herein.
- a further aspect of the invention provides an OMV composition, characterised in that each OMV in said composition comprises OMP and LPS from at least two different species of Neisseha.
- at least one of the species of Neisseha is a commensal Neisseha. It is further optional for one of the species to be a pathogenic species of Neisseha, for example N. meningitidis or N. gonorrhoeae.
- methods of preparing an OMV composition comprising the steps of:
- Also provided is a method for preparing a vaccine composition which method is substantially identical to the above-mentioned method, but which instead comprises the step of:
- Suitable methods for extracting OMVs from bacterial sources include deoxycholate extraction, Tris/HCI/EDTA extraction, and lithium acetate extraction. Protocols for performing such extractions are described in more detail in the Examples below. However, it will be appreciated by the skilled person that virtually any chemical and/or physical technique that enables disruption of the bacterial cell outer membrane in order to release sufficient OMVs for purification and isolation, would be suitable for preparation of the compositions of the invention
- combined OMVs are homogenised in a low power homogeniser (e.g. Waring blender or Silverson homogeniser or by ultrasonication).
- a low power homogeniser e.g. Waring blender or Silverson homogeniser or by ultrasonication.
- This additional step has the effect of disrupting the OMVs in the mixture such that they fuse to form hybrid OMVs.
- a single OMV can comprise OMPs, LPS and heterologous antigens from a plurality of bacterial sources.
- the fused chimaeric OMVs advantageously enable the presentation of multiple antigens to a host immune system in a uniquely immuno-available form.
- compositions of the invention provide methods of vaccinating animals, especially humans, against Gram negative bacterial infection utilising the compositions of the invention.
- the invention provides methods for vaccinating animals against meningococcal infection.
- uses of the compositions of the invention in the vaccination of animals, including humans, against Gram negative bacterial infection.
- uses of the compositions of the invention in the manufacture of vaccines for inoculating animals in order to stimulate protective immunity to Gram negative bacterial infection.
- OMVs are of use in mucosally administered compositions, as LPS toxicity is less and LPS can function as an adjuvant.
- Fig. 1 shows an electron micrograph of a preparation of N. meningitidis OMVs
- Fig. 2 shows an electron micrograph of a preparation of N. lactamica OMVs.
- Fig. 3 shows an electron micrograph of a blend of N. meningitidis
- N.lactamica OMVs according to the invention.
- Buffer 2 50mM Tris-HCI pH8.6 containing 2mM EDTA, 1.2% (w/v) DOC, 20%
- Buffer 3 50mM Tris-HCI pH8.6 containing 3% (w/v) sucrose, 0.01% (w/v) thiomersal
- Method 1 Appropriate N. meningitidis or commensal Neisseha strains were grown in Frantz medium at 37°C with shaking until cultures had reached early stationary phase.
- the culture was harvested by centrifugation, 5000 x g for 15min at 4°C
- buffer 1 was added using a ratio of buffer to biomass of 5 : 1(v/w).
- the suspension was centrifuged at 20,000 x g for 30min at 4°C and the supernatant retained.
- OMV preparation was stored at 4-8°C.
- Stock NOMV buffer 0.15M NaCI, 0.05M Tris-HCI, 0.01 M EDTA pH 7.5.
- the culture (Fe limited) was prepared in 500ml Frantz medium per strain. 2. Cells from the 500ml culture in step 1 were centrifuged at 3500 rpm for 15 minutes. 3. Cells were resuspended in 25ml NOMV buffer. 4. The suspension was warmed at 56°C for 30 minutes.
- the suspension was centrifuged at 23,500g for 20 minutes.
- the pellet was resuspended in 12ml distilled water and centrifuged at 23,500g for 20 minutes.
- the supernatant was retained and centrifuged at 100,000g for 2 hours 12.
- the pellet was washed by repelleting from distilled water.
- Lithium acetate buffer -200mM Lithium acetate + 5mM EDTA pH 6.0
- the broth culture (Fe limited) was prepared in 100ml MHB per strain.
- the suspension was incubated for 3h at 37°C with shaking (180rpm). 5. The cell suspension was then passed through a 21 gauge needle 7 times, alternatively a bead beater can be used.
- the suspension was centrifuged at 16000rpm for 20 minutes.
- the cell suspension was homogenised for 30min and the total wet weight of the suspension determined.
- the cell suspension was centrifuged for 60min at 2900 x g and the pellet resuspended in 0.1 M Tris-10mM EDTA buffer at a ratio of 7.5:1 wet weight
- the supernatant containing the vesicles was concentrated by ultracentrifugation at 125000 x g at 4°C for 2h.
- the OMV pellet was resuspended in 0.1 M Tris, 10Mm EDTA, 0.5% DOC buffer and the suspension centrifuged again at 125000 x g at 4°C for 2h. 8. The concentrated OMVs were resuspended in 3% sucrose solution
- OMV extracts were mixed in equimolar amounts with AIP0 4 as adjuvant.
- OMV extracts prepared according to any of the methods described in Examples 1-4 are obtained from N. meningitidis and N. lactamica. The OMV extracts are combined as per step 9 in Example 4.
- N. meningitidis and N. lactamica cultures are mixed together prior to performing the OMV extraction methods described in Examples 1-4.
- Concentrated OMVs are resuspended in 3% sucrose solution.
- OMV extracts are obtained from N. meningitidis and N. lactamica according to any of the methods given in Examples 1-4. Extracts of each are combined into a single composition and then homogenized. Concentrated OMVs are resuspended in 3% sucrose solution.
- Blocking buffer (2% bovine serum albumin in PBS)
- Conjugate buffer (0.02% Tween 20, 0.1% BSA, 5% newborn calf serum in PBS)
- N. lactamica (NL) and N. meningitidis (NM) OMVs were removed from storage at -20°C and allowed to thaw at room temperature.
- a mixture of OMVs was prepared separately by adding equal volumes of NL and NM OMVs to a glass container and agitating gently using a pipette; all OMVs were then stored at 4°C until required.
- NM, NL and the mixture of OMVs were placed on 3 separate carbon coated copper grids and allowed to dry.
- the grids were then placed in 100 ⁇ l of a 1 :500 dilution of meningococcal PorA monoclonal antibody and incubated at room temperature for 2h.
- the grids were washed twice in blocking buffer (PBS containing 2% BSA) and added to a 1 :20 dilution of 6nm colloidal gold particles conjugated to AffiniPure anti-mouse IgG (Jackson immuno Research
- Grids were washed twice in blocking buffer, once in distilled water and stained with 1 % potassium phosphotungstate (PTA) for 5-1 Osec. Grids were then examined by electron microscopy and are shown in Fig.s 1-3.
- PTA potassium phosphotungstate
- Black dots indicate labeling with the 6nm gold particles in Fig.s 1 , 2 and 3.
- NM OMVs are evenly labeled with the 6nm gold particles, showing that PorA is present on all OMVs.
- Fig.2 there is no labeling, consistent with the fact that NL OMVs do not contain PorA (a pathogen - specific antigen not seen in commensal Neisseria).
- the Fig. 3 result, showing the combination of NM and NL OMVs, shows OMVs again evenly labeled with the gold particles. The labeling is even, and is over all OMVs, not restricted to just a fraction of the OMVs.
- half the OMVs in the mixture originally contained no PorA, after blending all OMVs stain positively for PorA, indicating all OMVs now contain PorA.
- the invention provides vesicle-containing, especially OMV-based, preparations and methods for their production.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02785686A EP1476173A1 (en) | 2001-12-17 | 2002-12-17 | Outer membrane vesicles from gram negative bacteria and use as a vaccine |
JP2003552312A JP2005514388A (en) | 2001-12-17 | 2002-12-17 | Outer membrane vesicles from gram-negative bacteria and use as vaccines |
US10/499,063 US7384645B2 (en) | 2001-12-17 | 2002-12-17 | Outer membrane vesicles from gram negative bacteria and use as a vaccine |
CA002464512A CA2464512A1 (en) | 2001-12-17 | 2002-12-17 | Outer membrane vesicles from gram negative bacteria and use as a vaccine |
AU2002350974A AU2002350974B2 (en) | 2001-12-17 | 2002-12-17 | Outer membrane vesicles from gram negative bacteria and use as a vaccine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0130123.3 | 2001-12-17 | ||
GBGB0130123.3A GB0130123D0 (en) | 2001-12-17 | 2001-12-17 | Outer membrane vesicle vaccine and its preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003051379A1 true WO2003051379A1 (en) | 2003-06-26 |
Family
ID=9927760
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2002/005718 WO2003051379A1 (en) | 2001-12-17 | 2002-12-17 | Outer membrane vesicles from gram negative bacteria and use as a vaccine |
Country Status (7)
Country | Link |
---|---|
US (1) | US7384645B2 (en) |
EP (1) | EP1476173A1 (en) |
JP (1) | JP2005514388A (en) |
AU (1) | AU2002350974B2 (en) |
CA (1) | CA2464512A1 (en) |
GB (1) | GB0130123D0 (en) |
WO (1) | WO2003051379A1 (en) |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005035733A2 (en) * | 2003-10-09 | 2005-04-21 | Health Protection Agency | Modified whole cell, cell extract and omv-based vaccines |
WO2005042571A1 (en) * | 2003-11-04 | 2005-05-12 | Centro De Ingeniería Genética Y Biotecnología | Method of antigen incorporation into neisseria bacterial outer membrane vesicles and resulting vaccine formulations |
US7081244B2 (en) | 1999-02-22 | 2006-07-25 | Health Protection Agency | Neisserial vaccine compositions and methods |
US7157245B2 (en) * | 1999-02-22 | 2007-01-02 | Health Protection Agency | Neisserial vaccine compositions and methods |
CN101203529A (en) * | 2005-02-18 | 2008-06-18 | 诺华疫苗和诊断公司 | Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli |
US7820185B2 (en) | 2004-07-19 | 2010-10-26 | Health Protection Agency | Stable compositions containing OMVs |
EP2258717A2 (en) | 2002-11-22 | 2010-12-08 | Novartis Vaccines and Diagnostics S.r.l. | Variant form of meningococcal NadA |
EP2267036A1 (en) | 2003-10-02 | 2010-12-29 | Novartis Vaccines and Diagnostics S.r.l. | Hypo- and Hyper-Acetylated Meningococcal Capsular Saccharides |
EP2289546A2 (en) | 2003-01-30 | 2011-03-02 | Novartis Vaccines and Diagnostics S.r.l. | Injectable vaccines against multiple meningococcal serogroups |
WO2011024072A2 (en) | 2009-08-27 | 2011-03-03 | Novartis Ag | Hybrid polypeptides including meningococcal fhbp sequences |
WO2011051893A1 (en) | 2009-10-27 | 2011-05-05 | Novartis Ag | Modified meningococcal fhbp polypeptides |
WO2011077143A1 (en) | 2009-12-21 | 2011-06-30 | Health Protection Agency | Transformation of commensal neisseria |
EP2385126A1 (en) | 2005-11-25 | 2011-11-09 | Novartis Vaccines and Diagnostics S.r.l. | Chimeric, hybrid and tandem polypeptides of meningococcal NMB1870 |
EP2486940A2 (en) * | 2009-10-08 | 2012-08-15 | Aeon Medix Inc. | Composition comprising extracellular membrane vesicles derived from indoor air, and use thereof |
EP2505208A1 (en) * | 2011-04-01 | 2012-10-03 | University of Graz | Vaccine against Pasteurellaceae |
WO2013150142A1 (en) | 2012-04-05 | 2013-10-10 | Ludwig-Maximilians-Universität München | Method for the preparation of a strain- adapted vaccine |
US8968748B2 (en) | 2005-01-27 | 2015-03-03 | Children's Hospital & Research Center Oakland | GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis |
US8980285B2 (en) | 2000-07-27 | 2015-03-17 | Children's Hospital & Research Center At Oakland | Vaccines for broad spectrum protection against Neisseria meningitidis |
EP2886551A2 (en) | 2008-02-21 | 2015-06-24 | Novartis AG | Meningococcal fhbp polypeptides |
US9387239B2 (en) | 2008-05-30 | 2016-07-12 | U.S. Army Medical Research And Materiel Command | Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof |
WO2017103593A1 (en) * | 2015-12-15 | 2017-06-22 | University Of Southampton | Meningococcal infection and modified neisseria lactamica |
WO2019051380A1 (en) * | 2017-09-08 | 2019-03-14 | Evelo Biosciences, Inc. | Bacterial extracellular vesicles |
WO2019152667A1 (en) * | 2018-01-31 | 2019-08-08 | Evelo Biosciences, Inc. | Compositions and methods for treating immune disorders using lachnospiraceae bacteria |
WO2019157003A1 (en) * | 2018-02-06 | 2019-08-15 | Evelo Biosciences, Inc. | Compositions and methods for treating cancer and immune disorders using veillonella bacteria |
CN110478331A (en) * | 2018-11-19 | 2019-11-22 | 中国医学科学院医药生物技术研究所 | A kind of load medicine bacterial outer membrane vesicles and its preparation method and application |
CN110478319A (en) * | 2019-07-30 | 2019-11-22 | 中国医学科学院医药生物技术研究所 | A kind of antigen delivery system and the corresponding bacterial outer membrane vesicles and preparation method thereof with Modified antigen |
EP3693010A1 (en) | 2012-04-06 | 2020-08-12 | Cornell University | Subunit vaccine delivery platform for robust humoral and cellular immune responses |
EP3782643A1 (en) | 2014-02-28 | 2021-02-24 | GlaxoSmithKline Biologicals SA | Modified meningococcal fhbp polypeptides |
WO2021258180A1 (en) * | 2020-06-26 | 2021-12-30 | Instituto Butantan | Process for obtaining antigen-presenting vesicles (apv) that enables the coupling of one or more antigens |
US11534486B2 (en) | 2018-04-10 | 2022-12-27 | Administrators Of The Tulane Educational Fund | Burkholderia pseudomallei complex outer membrane vesicles as adjuvants |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9617671D0 (en) | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
US7192596B2 (en) * | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
US10967045B2 (en) * | 1998-11-02 | 2021-04-06 | Secretary of State for Health and Social Care | Multicomponent meningococcal vaccine |
GB9823978D0 (en) * | 1998-11-02 | 1998-12-30 | Microbiological Res Authority | Multicomponent meningococcal vaccine |
CN102580072A (en) | 1999-05-19 | 2012-07-18 | 诺华疫苗和诊断有限公司 | Combination neisserial compositions |
GB9928196D0 (en) | 1999-11-29 | 2000-01-26 | Chiron Spa | Combinations of B, C and other antigens |
GB0220194D0 (en) * | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
GB0316560D0 (en) | 2003-07-15 | 2003-08-20 | Chiron Srl | Vesicle filtration |
GB0419627D0 (en) * | 2004-09-03 | 2004-10-06 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
GB0424092D0 (en) | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
JP5279510B2 (en) | 2006-01-19 | 2013-09-04 | リサーチ コーポレイション テクノロジーズ,インコーポレイテッド | Viable non-toxic gram-negative bacteria |
JP2011503104A (en) | 2007-11-09 | 2011-01-27 | カリフォルニア インスティテュート オブ テクノロジー | Immunomodulatory compounds and related compositions and methods |
CN102480932B (en) * | 2009-09-01 | 2015-01-14 | 阿昂梅迪克斯公司 | Gut flora-derived extracellular vesicles, and method for searching for a disease model, vaccine, and candidate drug and for diagnosis using same |
WO2011027956A2 (en) | 2009-09-04 | 2011-03-10 | 주식회사이언메딕스 | Extracellular vesicles derived from gram-positive bacteria, and disease model using same |
KR20110082480A (en) | 2010-01-11 | 2011-07-19 | 포항공과대학교 산학협력단 | Composition comprising extracellular vesicles derived from mammals, and use thereof |
WO2011113003A1 (en) * | 2010-03-12 | 2011-09-15 | Research Corporation Technologies | Viable gram negative bacteria lacking outer membrane agonists of tlr4/md-2 |
US20110251156A1 (en) * | 2010-04-07 | 2011-10-13 | Yue Shen | Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems |
US20110287048A1 (en) * | 2010-05-20 | 2011-11-24 | Round June L | Antigen Specific Tregs and related compositions, methods and systems |
WO2012032498A2 (en) | 2010-09-10 | 2012-03-15 | Novartis Ag | Developments in meningococcal outer membrane vesicles |
PE20140222A1 (en) * | 2011-01-12 | 2014-03-12 | Univ Tulane | VACCINES BASED ON OMV AGAINST BURKHOLDERIA INFECTIONS |
EP2731617A4 (en) | 2011-07-12 | 2015-07-01 | Brigham & Womens Hospital | Lipid-containing psa compositions, methods of isolation and methods of use thereof |
EP2897635A1 (en) | 2012-09-18 | 2015-07-29 | Novartis AG | Outer membrane vesicles |
EP2953620A1 (en) * | 2013-02-07 | 2015-12-16 | GlaxoSmithKline Biologicals SA | Pharmaceutical compositions comprising vesicles |
WO2014182966A1 (en) | 2013-05-10 | 2014-11-13 | California Institute Of Technology | Probiotic prevention and treatment of colon cancer |
US10420833B2 (en) | 2014-05-19 | 2019-09-24 | Board Of Regents, The University Of Texas System | Combinatorial platform for the display of surface adjuvants and antigens |
BR102015013040B1 (en) * | 2015-06-03 | 2023-11-28 | Universidade Estadual De Campinas - Unicamp | Use of outer membrane vesicles (OMV) from the Haemophilus aegyptius 254 (Hae254) strain |
WO2016201342A1 (en) | 2015-06-10 | 2016-12-15 | California Institute Of Technology | Sepsis treatment and related compositions methods and systems |
CN113637040A (en) | 2015-08-19 | 2021-11-12 | 哈佛学院院长及董事 | Lipidated PSA compositions and methods |
KR101858840B1 (en) | 2016-01-15 | 2018-05-16 | 단국대학교 천안캠퍼스 산학협력단 | Immune modulator for the control of hypersensitivity due to house dust mite-derived allergens |
WO2017122915A1 (en) * | 2016-01-15 | 2017-07-20 | 단국대학교 천안캠퍼스 산학협력단 | Immunomodulator for hypersensitivity reaction to house dust mite-derived allergen |
US11491181B2 (en) | 2016-07-15 | 2022-11-08 | President And Fellows Of Harvard College | Glycolipid compositions and methods of use |
WO2018023000A1 (en) | 2016-07-29 | 2018-02-01 | The Regents Of The University Of Michigan | Recombinant gram negative bacteria and methods of generating and utilizing same |
KR101944660B1 (en) * | 2018-01-29 | 2019-01-31 | 주식회사 엠디헬스케어 | Method for diagnosis of depression using analysis of bacteria metagenome |
CN111454979B (en) * | 2020-04-03 | 2023-06-06 | 江苏省农业科学院 | Method for improving bacterial outer membrane vesicle yield and application thereof |
CN116870118B (en) * | 2023-07-11 | 2024-03-19 | 中山大学·深圳 | Hybrid membrane vesicle, preparation method and antibacterial application thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990006696A2 (en) * | 1988-12-19 | 1990-06-28 | Praxis Biologics, Inc. | Meningococcal class 1 outer-membrane protein vaccine |
WO2000025811A2 (en) * | 1998-11-02 | 2000-05-11 | Microbiological Research Authority Camr (Centre For Applied Microbiology & Research) | Multicomponent meningococcal vaccine |
WO2000050074A2 (en) * | 1999-02-22 | 2000-08-31 | Microbiological Research Authority | Neisserial vaccine compositions and methods |
WO2001009350A2 (en) * | 1999-08-03 | 2001-02-08 | Smithkline Beecham Biologicals S.A. | Genetically engineered bleb vaccine |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6180111B1 (en) * | 1995-05-18 | 2001-01-30 | University Of Maryland | Vaccine delivery system |
CA2182637A1 (en) | 1995-08-04 | 1997-02-05 | Jagath L. Kadurugamuwa | Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing them |
US6451317B1 (en) * | 1997-07-17 | 2002-09-17 | Baxter International Inc. | Immunogenic conjugates comprising a Group B meningococcal porin and an H influenzae polysaccharide |
US20030215469A1 (en) * | 1998-11-02 | 2003-11-20 | Microbiological Research Authority | Multicomponent meningococcal vaccine |
US7081244B2 (en) * | 1999-02-22 | 2006-07-25 | Health Protection Agency | Neisserial vaccine compositions and methods |
AU784518B2 (en) | 2000-01-17 | 2006-04-27 | Glaxosmithkline Biologicals S.A. | Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins |
NO20002828D0 (en) | 2000-06-02 | 2000-06-02 | Statens Inst For Folkehelse | Proteinaceous vaccine against Neisseria meningtidis serogroup and method of preparation thereof |
AU2001280883A1 (en) * | 2000-07-27 | 2002-02-13 | The Children's Hospital & Research Center At Oakland | Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
-
2001
- 2001-12-17 GB GBGB0130123.3A patent/GB0130123D0/en not_active Ceased
-
2002
- 2002-12-17 EP EP02785686A patent/EP1476173A1/en not_active Withdrawn
- 2002-12-17 WO PCT/GB2002/005718 patent/WO2003051379A1/en active Application Filing
- 2002-12-17 JP JP2003552312A patent/JP2005514388A/en active Pending
- 2002-12-17 US US10/499,063 patent/US7384645B2/en not_active Expired - Fee Related
- 2002-12-17 CA CA002464512A patent/CA2464512A1/en not_active Abandoned
- 2002-12-17 AU AU2002350974A patent/AU2002350974B2/en not_active Ceased
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990006696A2 (en) * | 1988-12-19 | 1990-06-28 | Praxis Biologics, Inc. | Meningococcal class 1 outer-membrane protein vaccine |
WO2000025811A2 (en) * | 1998-11-02 | 2000-05-11 | Microbiological Research Authority Camr (Centre For Applied Microbiology & Research) | Multicomponent meningococcal vaccine |
WO2000050074A2 (en) * | 1999-02-22 | 2000-08-31 | Microbiological Research Authority | Neisserial vaccine compositions and methods |
WO2001009350A2 (en) * | 1999-08-03 | 2001-02-08 | Smithkline Beecham Biologicals S.A. | Genetically engineered bleb vaccine |
Non-Patent Citations (2)
Title |
---|
BRACEGIRDLE P ET AL: "NEISSERIA LACTAMICA PROVIDES A CROSS-REACTIVE VACCINE AGAINST MENINGOCOCCAL DISEASE", PROGRAM AND ABSTRACTS OF THE INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, XX, XX, vol. 40, 17 September 2000 (2000-09-17), pages 248, XP008013997 * |
CARTWRIGHT K ET AL: "Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 17, no. 20-21, 4 June 1999 (1999-06-04), pages 2612 - 2619, XP004169673, ISSN: 0264-410X * |
Cited By (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7081244B2 (en) | 1999-02-22 | 2006-07-25 | Health Protection Agency | Neisserial vaccine compositions and methods |
US7157245B2 (en) * | 1999-02-22 | 2007-01-02 | Health Protection Agency | Neisserial vaccine compositions and methods |
US8980285B2 (en) | 2000-07-27 | 2015-03-17 | Children's Hospital & Research Center At Oakland | Vaccines for broad spectrum protection against Neisseria meningitidis |
EP2258717A2 (en) | 2002-11-22 | 2010-12-08 | Novartis Vaccines and Diagnostics S.r.l. | Variant form of meningococcal NadA |
EP2258716A2 (en) | 2002-11-22 | 2010-12-08 | Novartis Vaccines and Diagnostics S.r.l. | Multiple variants of meningococcal protein NMB1870 |
EP2261239A2 (en) | 2002-11-22 | 2010-12-15 | Novartis Vaccines and Diagnostics S.r.l. | Multiple variants of meningococcal protein NMB1870 |
EP2289546A2 (en) | 2003-01-30 | 2011-03-02 | Novartis Vaccines and Diagnostics S.r.l. | Injectable vaccines against multiple meningococcal serogroups |
EP2267036A1 (en) | 2003-10-02 | 2010-12-29 | Novartis Vaccines and Diagnostics S.r.l. | Hypo- and Hyper-Acetylated Meningococcal Capsular Saccharides |
WO2005035733A3 (en) * | 2003-10-09 | 2005-12-29 | Health Prot Agency | Modified whole cell, cell extract and omv-based vaccines |
WO2005035733A2 (en) * | 2003-10-09 | 2005-04-21 | Health Protection Agency | Modified whole cell, cell extract and omv-based vaccines |
WO2005042571A1 (en) * | 2003-11-04 | 2005-05-12 | Centro De Ingeniería Genética Y Biotecnología | Method of antigen incorporation into neisseria bacterial outer membrane vesicles and resulting vaccine formulations |
US7820185B2 (en) | 2004-07-19 | 2010-10-26 | Health Protection Agency | Stable compositions containing OMVs |
US9452208B2 (en) | 2005-01-27 | 2016-09-27 | Children's Hospital & Research Center Oakland | GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis |
US8968748B2 (en) | 2005-01-27 | 2015-03-03 | Children's Hospital & Research Center Oakland | GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis |
US10857221B2 (en) | 2005-01-27 | 2020-12-08 | Children's Hospital & Research Center At Oakland | GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis |
US9034345B2 (en) | 2005-01-27 | 2015-05-19 | Children's Hospital & Research Center Oakland | GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis |
US10478484B2 (en) | 2005-01-27 | 2019-11-19 | Children's Hospital & Research Center At Oakland | GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis |
US11801293B2 (en) | 2005-01-27 | 2023-10-31 | Children's Hospital & Research Center At Oakland | GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis |
US10046043B2 (en) | 2005-01-27 | 2018-08-14 | Children's Hospital & Research Center At Oakland | GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis |
CN101203529A (en) * | 2005-02-18 | 2008-06-18 | 诺华疫苗和诊断公司 | Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli |
EP2385127A1 (en) | 2005-11-25 | 2011-11-09 | Novartis Vaccines and Diagnostics S.r.l. | Chimeric, hybrid and tandem polypeptides of meningococcal NMB1870 |
EP3346009A1 (en) | 2005-11-25 | 2018-07-11 | GlaxoSmithKline Biologicals S.A. | Chimeric, hybrid and tandem polypeptides of meningococcal nmb1870 |
EP2385126A1 (en) | 2005-11-25 | 2011-11-09 | Novartis Vaccines and Diagnostics S.r.l. | Chimeric, hybrid and tandem polypeptides of meningococcal NMB1870 |
EP2886551A2 (en) | 2008-02-21 | 2015-06-24 | Novartis AG | Meningococcal fhbp polypeptides |
EP3263591A1 (en) | 2008-02-21 | 2018-01-03 | GlaxoSmithKline Biologicals S.A. | Meningococcal fhbp polypeptides |
US9387239B2 (en) | 2008-05-30 | 2016-07-12 | U.S. Army Medical Research And Materiel Command | Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof |
WO2011024072A2 (en) | 2009-08-27 | 2011-03-03 | Novartis Ag | Hybrid polypeptides including meningococcal fhbp sequences |
EP3017828A1 (en) | 2009-08-27 | 2016-05-11 | GlaxoSmithKline Biologicals SA | Hybrid polypeptides including meningococcal fhbp sequences |
EP2486940A2 (en) * | 2009-10-08 | 2012-08-15 | Aeon Medix Inc. | Composition comprising extracellular membrane vesicles derived from indoor air, and use thereof |
EP2486940A4 (en) * | 2009-10-08 | 2013-08-21 | Aeon Medix Inc | Composition comprising extracellular membrane vesicles derived from indoor air, and use thereof |
US8691522B2 (en) | 2009-10-08 | 2014-04-08 | Aeon Medix Inc. | Composition comprising extracellular membrane vesicles derived from indoor air, and use thereof |
WO2011051893A1 (en) | 2009-10-27 | 2011-05-05 | Novartis Ag | Modified meningococcal fhbp polypeptides |
WO2011077143A1 (en) | 2009-12-21 | 2011-06-30 | Health Protection Agency | Transformation of commensal neisseria |
WO2012131066A1 (en) | 2011-04-01 | 2012-10-04 | University Of Graz | Vaccine against pasteurellaceae |
EP2505208A1 (en) * | 2011-04-01 | 2012-10-03 | University of Graz | Vaccine against Pasteurellaceae |
WO2013150142A1 (en) | 2012-04-05 | 2013-10-10 | Ludwig-Maximilians-Universität München | Method for the preparation of a strain- adapted vaccine |
EP3693010A1 (en) | 2012-04-06 | 2020-08-12 | Cornell University | Subunit vaccine delivery platform for robust humoral and cellular immune responses |
EP3782643A1 (en) | 2014-02-28 | 2021-02-24 | GlaxoSmithKline Biologicals SA | Modified meningococcal fhbp polypeptides |
WO2017103593A1 (en) * | 2015-12-15 | 2017-06-22 | University Of Southampton | Meningococcal infection and modified neisseria lactamica |
US10960067B2 (en) | 2015-12-15 | 2021-03-30 | University Of Southampton | Meningococcal infection and modified Neisseria lactamica |
WO2019051380A1 (en) * | 2017-09-08 | 2019-03-14 | Evelo Biosciences, Inc. | Bacterial extracellular vesicles |
US11524037B2 (en) | 2017-09-08 | 2022-12-13 | Evelo Biosciences, Inc. | Bacterial extracellular vesicles |
WO2019152667A1 (en) * | 2018-01-31 | 2019-08-08 | Evelo Biosciences, Inc. | Compositions and methods for treating immune disorders using lachnospiraceae bacteria |
US11090341B2 (en) | 2018-02-06 | 2021-08-17 | Evelo Biosciences, Inc. | Compositions and methods for treating cancer and immune disorders using Veillonella bacteria |
WO2019157003A1 (en) * | 2018-02-06 | 2019-08-15 | Evelo Biosciences, Inc. | Compositions and methods for treating cancer and immune disorders using veillonella bacteria |
US11534486B2 (en) | 2018-04-10 | 2022-12-27 | Administrators Of The Tulane Educational Fund | Burkholderia pseudomallei complex outer membrane vesicles as adjuvants |
US11925681B2 (en) | 2018-04-10 | 2024-03-12 | The Administrators Of The Tulane Educational Fund | Burkholderia pseudomallei complex outer membrane vesicles as adjuvants |
CN110478331A (en) * | 2018-11-19 | 2019-11-22 | 中国医学科学院医药生物技术研究所 | A kind of load medicine bacterial outer membrane vesicles and its preparation method and application |
CN110478331B (en) * | 2018-11-19 | 2022-02-18 | 中国医学科学院医药生物技术研究所 | Drug-loaded bacteria outer membrane vesicle and preparation method and application thereof |
CN110478319A (en) * | 2019-07-30 | 2019-11-22 | 中国医学科学院医药生物技术研究所 | A kind of antigen delivery system and the corresponding bacterial outer membrane vesicles and preparation method thereof with Modified antigen |
WO2021258180A1 (en) * | 2020-06-26 | 2021-12-30 | Instituto Butantan | Process for obtaining antigen-presenting vesicles (apv) that enables the coupling of one or more antigens |
Also Published As
Publication number | Publication date |
---|---|
EP1476173A1 (en) | 2004-11-17 |
AU2002350974A1 (en) | 2003-06-30 |
AU2002350974B2 (en) | 2006-03-02 |
US7384645B2 (en) | 2008-06-10 |
CA2464512A1 (en) | 2003-06-26 |
GB0130123D0 (en) | 2002-02-06 |
JP2005514388A (en) | 2005-05-19 |
US20050013831A1 (en) | 2005-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002350974B2 (en) | Outer membrane vesicles from gram negative bacteria and use as a vaccine | |
Li et al. | Bacterial outer membrane vesicles as a platform for biomedical applications: An update | |
EP1126874B1 (en) | Multicomponent meningococcal vaccine | |
CA2086831C (en) | Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them | |
US6558677B2 (en) | Vaccine against gram negative bacteria | |
Wright et al. | Immunization with the recombinant PorB outer membrane protein induces a bactericidal immune response against Neisseria meningitidis | |
JP2016105736A (en) | Hyperblebbing shigella strains | |
Conlan et al. | Immunization of mice with lipopeptide antigens encapsulated in novel liposomes prepared from the polar lipids of various Archaeobacteria elicits rapid and prolonged specific protective immunity against infection with the facultative intracellular pathogen, Listeria monocytogenes | |
JP2006500963A (en) | Vaccine composition | |
JP2002508761A (en) | VODETELLA PERTUSSIS Pili-Containing Vaccination Conjugates and BORDETELLA PERTUSSIS Antigen as Carrier in Oral Vaccines | |
JP2001510169A (en) | Meningococcal type B porin and H. Immunogenic conjugates comprising influenzae polysaccharides | |
EP0944397A1 (en) | Iscom or iscom-matrix comprising hydrophobic receptor molecules for antigenic substances | |
Haque et al. | S. Typhi derived vaccines and a proposal for outer membrane vesicles (OMVs) as potential vaccine for typhoid fever | |
CN109069424A (en) | Liposome bacterin | |
Childers et al. | Mucosal and systemic responses to an oral liposome-Streptococcus mutans carbohydrate vaccine in humans. | |
RU2186582C2 (en) | Method of isolation and purification of protein of moraxella catarrhalis external membrane, strain moraxella catarrhalis for preparing protein cd, isolated and purified nondenaturated protein cd of moraxella catarrhalis external membrane and immunogenic composition comprising protein cd of moraxella catarrhalis external membrane | |
Christodoulides et al. | The potential utility of liposomes for Neisseria vaccines | |
EP1687011B1 (en) | Modified whole cell, cell extract and omv-based vaccines | |
EP2429658B1 (en) | Method for adjuvating the lipopolysaccharide (LPS) of gram-negative bacteria | |
WO2004054611A1 (en) | Meningococcal vaccine based on outer membrane proteins porb2 and pora | |
Idänpään-Heikkilä et al. | Immunization with meningococcal class 1 outer membrane protein produced in Bacillus subtilis and reconstituted in the presence of Zwittergent or Triton X-100 | |
EP2429576A1 (en) | Meningococcal vaccine based on lipooligosaccharide (los) and neisseria meningitidis protein | |
Lowell et al. | Proteosome™ technology for vaccines and adjuvants | |
Kalambaheti et al. | CpG DNA, Liposome and Refined Anti-gen Oral Cholera Vaccine | |
WO2010130898A2 (en) | Menigococcus vaccine containing lipooligosaccharide (los) from modified strains of l6 immunotype neisseria meningitidis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2464512 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003552312 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10499063 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002350974 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002785686 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002785686 Country of ref document: EP |